Rab8 and Rabin8-Mediated Tumor Formation by Hyperactivated EGFR Signaling via FGFR Signaling

Choi, Jong-Soo; Sung, Jee Young; Lee, Saerom; Yoo, Jungyoen; Rongo, Christopher; Kim, Yong Nyun; Shim, Ju Hyun

doi:10.3390/ijms21207770

Cited by 5 publications

(3 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the exocytic transport to the PM, Rab8 and Rabin8, a GEF of Rab8, are required for fibroblast growth factor (FGF) 2 secretion to promote the EGF receptor (EGFR) signaling pathway which contributes to lung cancer malignancy [32]. In addition, Rab25 promotes or blocks tumor growth through the chloride intracellular channel protein 3 protein which is necessary for Rab25-mediated integrin recycling from late endosomes/lysosomes and drive cancer progression [33].…”

Section: Exocytic Trafficking Of Membrane Proteins In Cancer Cellsmentioning

confidence: 99%

Recent advances in conventional and unconventional vesicular secretion pathways in the tumor microenvironment

et al. 2022

View full text Add to dashboard Cite

All cells in the changing tumor microenvironment (TME) need a class of checkpoints to regulate the balance among exocytosis, endocytosis, recycling and degradation. The vesicular trafficking and secretion pathways regulated by the small Rab GTPases and their effectors convey cell growth and migration signals and function as meditators of intercellular communication and molecular transfer. Recent advances suggest that Rab proteins govern conventional and unconventional vesicular secretion pathways by trafficking widely diverse cargoes and substrates in remodeling TME. The mechanisms underlying the regulation of conventional and unconventional vesicular secretion pathways, their action modes and impacts on the cancer and stromal cells have been the focus of much attention for the past two decades. In this review, we discuss the current understanding of vesicular secretion pathways in TME. We begin with an overview of the structure, regulation, substrate recognition and subcellular localization of vesicular secretion pathways. We then systematically discuss how the three fundamental vesicular secretion processes respond to extracellular cues in TME. These processes are the conventional protein secretion via the endoplasmic reticulum-Golgi apparatus route and two types of unconventional protein secretion via extracellular vesicles and secretory autophagy. The latest advances and future directions in vesicular secretion-involved interplays between tumor cells, stromal cell and host immunity are also described.

show abstract

Section: Exocytic Trafficking Of Membrane Proteins In Cancer Cellsmentioning

confidence: 99%

Recent advances in conventional and unconventional vesicular secretion pathways in the tumor microenvironment

et al. 2022

View full text Add to dashboard Cite

show abstract

“…And there has been a promising prognosis predicting model for melanoma based on TBC family protein (Tang D. et al, 2020). Furthermore, Rab8 and Rabin8 (the GEF of Rab8) promote tumor formation (Choi et al, 2020).…”

Section: Rab Gtpase Function In Membrane Traffickingmentioning

confidence: 99%

Rab GTPases: Central Coordinators of Membrane Trafficking in Cancer

Jin

Tang

Yang

et al. 2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Tumor progression involves invasion, migration, metabolism, autophagy, exosome secretion, and drug resistance. Cargos transported by membrane vesicle trafficking underlie all of these processes. Rab GTPases, which, through coordinated and dynamic intracellular membrane trafficking alongside cytoskeletal pathways, determine the maintenance of homeostasis and a series of cellular functions. The mechanism of vesicle movement regulated by Rab GTPases plays essential roles in cancers. Therefore, targeting Rab GTPases to adjust membrane trafficking has the potential to become a novel way to adjust cancer treatment. In this review, we describe the characteristics of Rab GTPases; in particular, we discuss the role of their activation in the regulation of membrane transport and provide examples of Rab GTPases regulating membrane transport in tumor progression. Finally, we discuss the clinical implications and the potential as a cancer therapeutic target of Rab GTPases.

show abstract

“…As a result, osimertinib is approved for both first-line treatment of patients with T790M-positive and advanced EGFR -mutated NSCLC who have progressed on first- or second-generation EGFR-TKIs [ 15 ]. Currently, other third-generation EGFR-TKIs targeting the T790M mutation, such as Rociletinib, Olmutinib, Nazartinib, and Naquotinib are under clinical evaluation in addition to osimertinib [ 17 , 18 ].…”

Section: Introductionmentioning

confidence: 99%

Toward the next generation EGFR inhibitors: an overview of osimertinib resistance mediated by EGFR mutations in non-small cell lung cancer

Mao

Wang

et al. 2023

Cell Commun Signal

View full text Add to dashboard Cite

Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) is currently the standard first-line therapy for EGFR-mutated advanced non-small cell lung cancer (NSCLC). The life quality and survival of this subgroup of patients were constantly improving owing to the continuous iteration and optimization of EGFR-TKI. Osimertinib, an oral, third-generation, irreversible EGFR-TKI, was initially approved for the treatment of NSCLC patients carrying EGFR T790M mutations, and has currently become the dominant first-line targeted therapy for most EGFR mutant lung cancer. Unfortunately, resistance to osimertinib inevitably develops during the treatment and therefore limits its long-term effectiveness. For both fundamental and clinical researchers, it stands for a major challenge to reveal the mechanism, and a dire need to develop novel therapeutics to overcome the resistance. In this article, we focus on the acquired resistance to osimertinib caused by EGFR mutations which account for approximately 1/3 of all reported resistance mechanisms. We also review the proposed therapeutic strategies for each type of mutation conferring resistance to osimertinib and give an outlook to the development of the next generation EGFR inhibitors.

show abstract

Rab8 and Rabin8-Mediated Tumor Formation by Hyperactivated EGFR Signaling via FGFR Signaling

Cited by 5 publications

References 49 publications

Recent advances in conventional and unconventional vesicular secretion pathways in the tumor microenvironment

Recent advances in conventional and unconventional vesicular secretion pathways in the tumor microenvironment

Rab GTPases: Central Coordinators of Membrane Trafficking in Cancer

Toward the next generation EGFR inhibitors: an overview of osimertinib resistance mediated by EGFR mutations in non-small cell lung cancer

Contact Info

Product

Resources

About